Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. reported higher quarterly results for the three months ended March 31, 2026. Total revenues rose to $8.6 billion from $8.1 billion a year earlier, driven by product sales of $8.2 billion, notably from Repatha, Prolia, EVENITY, TEPEZZA and other key therapies.
Net income increased to $1.8 billion from $1.7 billion, with diluted EPS of $3.34 versus $3.20. Operating income more than doubled to $2.7 billion, helped by lower cost of sales and the absence of prior-year intangible impairments, partly offset by higher R&D spending.
Cash from operating activities rose to $2.2 billion, and cash and cash equivalents reached $12.0 billion, while total assets were $92.5 billion and total debt $58.8 billion. The company continues to face tax disputes with the IRS that could be material and highlighted regulatory scrutiny of TAVNEOS and pricing pressures from U.S. policy changes, including the Inflation Reduction Act.
Amgen Inc. reported solid first quarter 2026 results, with total revenues rising 6% to $8.6 billion, supported by 4% product sales growth driven by 9% higher volumes. Sixteen products delivered double-digit sales growth and seventeen are tracking at more than $1 billion in annualized sales.
GAAP earnings per share increased from $3.20 to $3.34, while non-GAAP EPS grew from $4.90 to $5.15. GAAP operating income rose from $1.2 billion to $2.7 billion, expanding GAAP operating margin to 32.4%, though non-GAAP operating margin edged down to 45.3%.
The company generated $1.5 billion of free cash flow versus $1.0 billion a year earlier and paid a quarterly dividend of $2.52 per share, up 6%. Management reaffirmed the use of extensive non-GAAP measures and guided 2026 non-GAAP diluted EPS to a range of $21.70–$23.10, compared with GAAP EPS guidance of $15.62–$17.10.
Amgen Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 40,510,484 shares of Amgen common stock, representing 7.51% of the class as of 03/31/2026. The filing shows 5,496,252 shares with sole voting power and 40,510,484 shares with sole dispositive power.
Amgen Inc. announced that David M. Reese, M.D., executive vice president and Chief Technology Officer, will retire from his executive roles effective June 30, 2026. He will remain an executive vice president until that date and receive retirement benefits under existing company plans.
To support Amgen’s focus on combining biology, data science and advanced technologies, the company is redistributing Reese’s responsibilities effective June 1, 2026. James Bradner, M.D., will serve as executive vice president, Research and Development, Artificial Intelligence and Data; Sean Bruich will become senior vice president and Chief Technology Officer; and Murdo Gordon will lead Amgen Global Markets and Policy as executive vice president. These changes are intended to deepen the integration of science and technology across research, medical, commercial and policy functions.
Amgen Inc. is asking stockholders to vote at its May 19, 2026 virtual annual meeting on four items: electing 12 directors, an advisory “Say on Pay” vote, ratifying Ernst & Young as auditor for 2026, and a stockholder proposal for an independent board chair, which the Board recommends voting against.
The proxy highlights strong 2025 execution, including 10% year-over-year revenue and sales growth, record sales for 18 products, 14 products each exceeding $1 billion in sales, and five U.S. FDA approvals. Amgen reports 37% sales growth in its biosimilar portfolio to $3 billion and notes that more than 25% of revenue comes from non-U.S. markets.
The company is investing heavily in U.S. manufacturing, following a prior $1 billion North Carolina expansion with additional commitments of $900 million in Ohio and $650 million in Puerto Rico, aimed at boosting capacity, yields, and supply resilience. Executive pay is described as performance-based, with 80% of annual long-term equity awards tied to performance and a 2025 annual incentive plan payout at 136% of target based on financial and strategic results.
The Vanguard Group filed Amendment No. 11 on a Schedule 13G/A reporting 0 shares of Amgen Inc. common stock. The filing states that, following an internal realignment on 01/12/2026, certain Vanguard subsidiaries now report beneficial ownership separately pursuant to SEC Release No. 34-39538 (01/12/1998), and The Vanguard Group no longer is deemed to beneficially own securities held by those subsidiaries. The amendment lists Amount beneficially owned: 0 and Percent of class: 0%, with all voting and dispositive powers shown as 0.
Amgen Inc. executive Esteban Santos, EVP of Operations, reported an automatic share disposition tied to taxes rather than an open-market trade. On March 16, 2026, 5,621 shares of common stock were transferred at $366.21 per share to satisfy a tax liability by delivering securities.
After this transaction, Santos directly holds 82,404 common shares, which include 696 Dividend Equivalents that will pay out in shares as restricted stock units vest. He also has an additional indirect holding of 909.9928 shares through Amgen's 401(k) Plan stock fund.
AMGEN INC executive David M. Reese reported a compensation-related share disposition tied to tax obligations. On March 16, 2026, 6,022 shares of Amgen common stock were delivered at $366.21 per share to satisfy tax liability or exercise costs, a transaction coded as tax-withholding. Following this event, Reese directly held 41,787 Amgen shares. A portion of his position also reflects dividend equivalents credited to unvested restricted stock units that will be paid in shares as they vest.
Amgen Inc. senior vice president Derek Miller reported a routine tax-withholding transaction in company stock. On March 16, 2026, 1,616 shares of Amgen common stock were disposed of at $366.21 per share to satisfy tax obligations related to equity compensation. Following this withholding, Miller directly holds 12,173 shares, which include 197 dividend equivalents tied to unvested restricted stock units that will pay out in shares as they vest.